Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)
Johnson & Johnson's (JNJ) quarterly Liabilities from Discontinued Operations came in at $3.6 billion in Q1 2023.
Analysis
Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends
Johnson & Johnson has disclosed Liabilities from Discontinued Operations across 1 years of filings, most recently posting $3.6 billion for Q1 2023.
- In Q1 2023, Liabilities from Discontinued Operations changed N/A year-over-year to $3.6 billion; the TTM figure through Jan 2023 stood at $3.6 billion (changed N/A YoY), while the FY2023 annual figure was $3.6 billion, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at $3.6 billion for Q1 2023 at Johnson & Johnson.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of $3.6 billion in Q1 2023 to a low of $3.6 billion in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |